Metastatic ovarian disease following surgical management of grade 1 endometrial endometrioid adenocarcinoma confined to the endometrium; a case report and review of the literature.

Endometrial Cancer FIGO Stage 1a Grade 1 Endometrioid Adenocarcinoma Metastatic Ovarian Cancer

Journal

Gynecologic oncology reports
ISSN: 2352-5789
Titre abrégé: Gynecol Oncol Rep
Pays: Netherlands
ID NLM: 101652231

Informations de publication

Date de publication:
Oct 2022
Historique:
received: 03 06 2022
revised: 26 07 2022
accepted: 01 08 2022
entrez: 15 8 2022
pubmed: 16 8 2022
medline: 16 8 2022
Statut: epublish

Résumé

Endometrial endometrioid type cancer is a common gynaecological cancer for which the standard surgical management includes hysterectomy and bilateral salpingo-oophorectomy. The value of oophorectomy is to remove occult ovarian disease. It is estimated that 5 % of low grade endometrioid adenocarcinoma will have concurrent ovarian involvement (3 % synchronous tumours, 2 % ovarian metastases), of which only 1 % will be microscopic. Ovarian preservation at the time of surgery can be considered, especially in early-stage disease or premenopausal women. We describe a case of metastatic ovarian disease following surgical management of grade 1 endometrial endometrioid adenocarcinoma confined to the endometrium (FIGO stage 1a), in a postmenopausal woman who declined primary oophorectomy. This case was without genetic predisposition and recurred 12 months after initial surgical treatment. This case is incongruent with what has previously been understood for FIGO stage 1a endometrial endometrioid adenocarcinoma and highlights that even disease seemingly confined to the endometrium can metastasise microscopically to the ovaries.

Identifiants

pubmed: 35967832
doi: 10.1016/j.gore.2022.101061
pii: S2352-5789(22)00141-2
pmc: PMC9372595
doi:

Types de publication

Case Reports

Langues

eng

Pagination

101061

Informations de copyright

© 2022 The Authors.

Déclaration de conflit d'intérêts

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Références

Eur J Obstet Gynecol Reprod Biol. 2021 Dec;267:245-255
pubmed: 34837854
Gynecol Oncol. 2020 Jun;157(3):619-623
pubmed: 32247604
Lancet. 2016 Mar 12;387(10023):1094-1108
pubmed: 26354523
Acta Obstet Gynecol Scand. 2004 Feb;83(2):208-10
pubmed: 14756742
J Clin Oncol. 2019 Sep 20;37(27):2490-2500
pubmed: 31403860
Int J Gynecol Cancer. 2017 Jan;27(1):77-84
pubmed: 27922977
Asian Pac J Cancer Prev. 2008 Jul-Sep;9(3):403-7
pubmed: 18990010
Cancers (Basel). 2020 Nov 10;12(11):
pubmed: 33182707
J Natl Compr Canc Netw. 2018 Feb;16(2):170-199
pubmed: 29439178
J Natl Cancer Inst. 2016 Feb 01;108(6):djv427
pubmed: 26832770
Int J Fertil Steril. 2011 Oct;5(3):148-51
pubmed: 25101158
Gynecol Oncol. 2015 Sep;138(3):532-5
pubmed: 26186908
Int J Gynecol Cancer. 2017 Oct;27(8):1694-1700
pubmed: 28786874

Auteurs

Sophia Hill (S)

Gynaecologic Oncology, Chris O'Brien Lifehouse, Camperdown 2050, Australia.

Lyndal Anderson (L)

Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Camperdown 2050, Australia.
Sydney Medical School, University of Sydney, Camperdown 2006, Australia.
Western Sydney University, Penrith 2751, Australia.

Selvan Pather (S)

Gynaecologic Oncology, Chris O'Brien Lifehouse, Camperdown 2050, Australia.
Sydney Medical School, University of Sydney, Camperdown 2006, Australia.

Classifications MeSH